英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
frenata查看　frenata　在百度字典中的解释百度英翻中〔查看〕
frenata查看　frenata　在Google字典中的解释Google英翻中〔查看〕
frenata查看　frenata　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA Approves Label Update for Nadofaragene Firadenovec in . . .
    The FDA approved a label change for nadofaragene firadenovec-vncg (Adstiladrin) in non–muscle-invasive bladder cancer to improve preparation time
  • Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
    Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
  • ADSTILADRIN | FDA
    ADSTILADRIN is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS
  • U. S. FDA Approves Label Update to Accelerate Thaw Time for . . .
    ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta T1)
  • Mechanism of action of nadofaragene firadenovec-vncg - PMC
    Nadofaragene firadenovec-vncg (Adstiladrin ®) was approved by the US Food and Drug Administration as the first gene therapy in urology and the first intravesical gene therapy indicated for the treatment of adult patients with high-risk bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or
  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
    Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA SUO Guidelines1 By the International Bladder Cancer Group (IBCG) for high-risk NMIBC after BCG failure for those seeking to avoid radical cystectomy 2
  • First Bladder Cancer Patient Dosed with Commercially . . .
    First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) Urologists treating eligible high-risk bladder cancer patients at participating early experience program clinics in the U S can now prescribe the first and only FDA-approved intravesical gene therapy
  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | NMIBC Treatment
    STIL DOING IT MY WAY With ADSTILADRIN Meet Mike, an actual patient who decided with his doctor to stay on ADSTILADRIN for over 6 years He remains cancer free today What’s His Way? Individual results may vary Abbreviations: BCG, Bacillus Calmette-Guérin; NMIBC, non–muscle-invasive bladder cancer
  • Ferring Receives Approval from U. S. FDA for Adstiladrin for . . .
    Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and safety of Adstiladrin supported by Phase 3 results demonstrating that more than half of patients (51% of CIS ± Ta T1 cohort) achieved a complete response (CR) at three months and of these, 46% continued to remain free of high
  • FDA updates in urology: March 2026 | Urology Times
    On March 24, 2026, Ferring Pharmaceuticals announced FDA approval of a label update for nadofaragene firadenovec-vncg (Adstiladrin) to introduce an accelerated thawing protocol for patients with high-risk BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ 4 This approval is based on a thawing and handling study





中文字典-英文字典  2005-2009